Posted by Michael Wonder on 28 Sep 2020
Blueprint Medicines announces European Commission approval of Ayvakyt (avapritinib) for the treatment of adults with unresectable or metastatic PDGFRA D842V mutant gastro-intestinal stromal tumours
25 September 2020 - First highly effective treatment option approved in Europe for PDGFRA D842V mutant GIST.
Blueprint Medicines today announced that the European Commission has granted conditional marketing authorisation to Ayvakyt (avapritinib) as a monotherapy for the treatment of adult patients with unresectable or metastatic gastro-intestinal stromal tumours (GIST) harbouring the platelet-derived growth factor receptor alpha (PDGFRA) D842V mutation.
For the first time in Europe, there is an approved therapy for patients with PDGFRA D842V mutant GIST specifically designed to target the underlying molecular driver of their disease.
